Immunogenicity of a subunit vaccine against Bacillus anthracis.
Vaccine
; 25(16): 3111-4, 2007 Apr 20.
Article
em En
| MEDLINE
| ID: mdl-17280756
ABSTRACT
The current approved vaccine against anthrax is based on protective antigen (PA) of Bacillus anthracis, requires six injections over an 18-month period and has a known history of side effects. Therefore, there is significant effort towards developing an improved vaccine against B. anthracis. Here we separately engineered and expressed domain 4 of PA (PAD4) and domain 1 of lethal factor (LFD1) as fusions to lichenase (LicKM), a thermostable enzyme from Clostridium thermocellum, and transiently expressed these fusions in Nicotiana benthamiana. Plant-produced antigens were combined and immunogenicity was evaluated in mice. All animals that received the experimental vaccine developed high antibody titers that were predominantly IgG1 and were able to neutralize the effects of LeTx in vitro.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Bacillus anthracis
/
Vacinas Sintéticas
/
Vacinas contra Antraz
/
Vacinas de Subunidades Antigênicas
/
Antraz
Limite:
Animals
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos